Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis

World Journal of Gastroenterology

Volumn 23, Issue 2, 2017, Pages 336-344

  Cayzeele Decherf, Amélie ^a   Pélerin, Fanny ^a   Leuillet, Sébastien ^b   Douillard, Benoit ^b   Housez, Béatrice ^b   Cazaubiel, Murielle ^b   Jacobson, Gunnard K ^c   Jüsten, Peter ^a   Desreumaux, Pierre ^d,e,f  

^a Lesaffre International   (France)

^b Biofortis Mérieux NutriSciences Company   (France)

^c Lesaffre Group   (United States)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIV LILLE   (France)

^f UNIVERSITÉ DE LILLE   (France)

Author keywords

Abdominal pain; Constipation; Irritable bowel syndrome; Probiotics; Saccharomyces cerevisiae

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; BLOATING; DRUG EFFICACY; DRUG RESPONSE; FUNGAL STRAIN; GASTROINTESTINAL SYMPTOM; HUMAN; INTENTION TO TREAT ANALYSIS; INTESTINE MOTILITY; IRRITABLE COLON; LIKERT SCALE; META ANALYSIS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SACCHAROMYCES CEREVISIAE; SUPPLEMENTATION; ADULT; BIOLOGICAL THERAPY; COMPLICATION; CONSTIPATION; DEFECATION; DRUG EFFECTS; FEMALE; FLATULENCE; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADULT; BIOLOGICAL THERAPY; CONSTIPATION; DEFECATION; FEMALE; FLATULENCE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME;

EID: 85009164511     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i2.336     Document Type: Article

References (33)

1. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71-80 [PMID: 24523597 DOI: 10.2147/CLEP.S40245]
2. Soares RL. Irritable bowel syndrome: a clinical review. World J Gastroenterol 2014; 20: 12144-12160 [PMID: 25232249 DOI: 10.3748/wjg.v20.i34.12144]
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1053/j.gastro.2005.11.061]
4. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 2014; 20: 6759-6773 [PMID: 24944467 DOI: 10.3748/wjg.v20.i22.6759]
5. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-176 [PMID: 22730468 DOI: 10.1136/gutjnl-2012-302167]
6. Bennet SM, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver 2015; 9: 318-331 [PMID: 25918261 DOI: 10.5009/gnl14344]
7. Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014; 20: 8886-8897 [PMID: 25083061 DOI: 10.3748/wjg.v20.i27.8886]
8. Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 2014; 20: 8898-8909 [PMID: 25083062 DOI: 10.3748/wjg.v20.i27.8898]
9. Santos AR, Whorwell PJ. Irritable bowel syndrome: the problem and the problem of treating it - is there a role for probiotics? Proc Nutr Soc 2014; 73: 470-476 [PMID: 25156472 DOI: 10.1017/S0029665114000706]
10. Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 2015; 47: 119-124 [PMID: 25488056 DOI: 10.1016/j.dld.2014.11.007]
11. Spiller R, Pélerin F, Cayzeele Decherf A, Maudet C, Housez B, Cazaubiel M, Jüsten P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterol J 2016; 4: 353-362 [PMID: 27403301 DOI: 10.1177/2050640615602571]
12. Kurtzman CP, Robnett CJ. Identification and phylogeny of ascomycetous yeasts from analysis of nuclear large subunit (26S) ribosomal DNA partial sequences. Antonie Van Leeuwenhoek 1998; 73: 331-371 [PMID: 9850420]
13. Kurtzman CP, Robnett CJ. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′ end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol 1997; 35: 1216-1223 [PMID: 9114410]
14. Standardization ECf. Animal feeding stuffs: PCR typing of probiotic strains of Saccharomyces cerevisiae (yeast)
15. Borenstein M, Hedges L, Rothstein H. Meta-analysis: Fixed effect vs random effects. Available from: URL: http://www.Meta-Analysis.com
16. Whitehead A. Meta-Analysis of Controlled Clinical Trials: John Wiley and Sons, Ltd, 2003
17. Shah E, Pimentel M. Placebo effect in clinical trial design for irritable bowel syndrome. J Neurogastroenterol Motil 2014; 20: 163-170 [PMID: 24840369 DOI: 10.5056/jnm.2014.20.2.163]
18. Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007; 13: 3425-3429 [PMID: 17659688 DOI: 10.3748/wjg.v13.i25.3425]
19. Rousseaux C, Bouguen G, Dubuquoy C, Dubuquoy L, Vandekerckove P, Desreumaux P. 274 Sacharomyces Cerevisiae Cncm I-3856 Decreases Intestinal Pain Through PPAR Alpha Activation in the Gut. Gastroenterology 2010; 138: S-51 [DOI: 10.1016/S0016-5085(10)60232-6]
20. Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014; 147: 1149-1172.e2 [PMID: 25224525 DOI: 10.1053/j.gastro.2014.09.002]
21. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538-1551 [PMID: 16678567 DOI: 10.1053/j.gastro.2005.11.058]
22. Food and Drug Administration. Guidance for Industry: Irritable Bowel Syndrome - Clinical Evaluation of Drugs for Treatment. US Department of Health and Human services, Food and Drug Administration, Center for Drug Evalution and research (CDER), 2012: 17
23. European Medicines Agency. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. European Medicines Agency, 2014: 18
24. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 144-158 [PMID: 20412064 DOI: 10.1111/j.1365-2036.2010.04328.x]
25. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, Canenguez K, Park JK, Kelly E, Jacobson E, Kerr CE, Lembo AJ. The placebo effect in irritable bowel syndrome trials: a metaanalysis. Neurogastroenterol Motil 2005; 17: 332-340 [PMID: 15916620 DOI: 10.1111/j.1365-2982.2005.00650.x]
26. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 15 [PMID: 19220890 DOI: 10.1186/1471-230X-9-15]
27. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-2661 [PMID: 18461650 DOI: 10.3748/wjg.14.2650]
28. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-332 [PMID: 19091823 DOI: 10.1136/gut.2008.167270]
29. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 2015; 21: 3072-3084 [PMID: 25780308 DOI: 10.3748/wjg.v21.i10.3072]
30. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1547-1561; quiz 1546, 1562 [PMID: 25070051 DOI: 10.1038/ajg.2014.202]
31. Ortiz-Lucas M, Tobías A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig 2013; 105: 19-36 [PMID: 23548007]
32. Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a metaanalysis. Intern Med 2015; 54: 243-249 [PMID: 25748731 DOI: 10.2169/internalmedicine.54.2710]
33. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 2011; 33: 1302-1310 [PMID: 21507030 DOI: 10.1111/j.1365-2036.2011.04665.x]